Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients

Rechallenging With Intrathecal Methotrexate After Developing Subacute Neurotoxicity in Children With Hematologic Malignancies

(2015) Colleen Badke et al.   PEDIATRIC BLOOD & CANCER

Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia

(2014) Deepa Bhojwani et al.   JOURNAL OF CLINICAL ONCOLOGY

Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia

(2014) U. Löbel et al.   PEDIATRIC BLOOD & CANCER

Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia

(2013) S. Radtke et al.   BLOOD

Leukoencephalopathy due to Oral Methotrexate

(2013) I. González-Suárez et al.   CEREBELLUM

Accelerated Aging, Decreased White Matter Integrity, and Associated Neuropsychological Dysfunction 25 Years After Pediatric Lymphoid Malignancies

(2013) Ilse Schuitema et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

(2013) Ajay Vora et al.   LANCET ONCOLOGY

Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist

(2011) Veena Vijayanathan et al.   BEHAVIOURAL BRAIN RESEARCH

Effect of Proton Pump Inhibitors on Vitamins and Iron

(2009) Kenneth E L McColl   AMERICAN JOURNAL OF GASTROENTEROLOGY

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy

(2008) Kunihiro Suzuki et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY